These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15960943)

  • 1. [Effectiveness and safety of the treatment with tumour necrosis factor alpha antagonists in rheumatoid arthritis patients].
    Arenere Mendoza M; Navarro Aznárez H; Rabanaque Hernández MJ; Manero Ruiz FJ
    Med Clin (Barc); 2005 Jun; 125(1):35-6. PubMed ID: 15960943
    [No Abstract]   [Full Text] [Related]  

  • 2. Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience.
    Salgado E; Campos J; Moreira-Navarrete V; Mulero J; Navarro F; Pérez-Pampín E; Carmona L; Gómez-Reino J
    Joint Bone Spine; 2013 Jul; 80(4):438-40. PubMed ID: 23453477
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-tumour necrosis factor alpha therapy in patients with impaired renal function.
    Hueber AJ; Tunc A; Schett G; Manger B
    Ann Rheum Dis; 2007 Jul; 66(7):981-2. PubMed ID: 17337474
    [No Abstract]   [Full Text] [Related]  

  • 4. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
    Choy E
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
    Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.
    Sandoo A; Dimitroulas T; Toms TE; Hodson J; Veldhuijzen van Zanten JJ; Smith JP; Kitas GD
    Clin Biochem; 2012 Nov; 45(16-17):1399-403. PubMed ID: 22820438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
    Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
    Reumatizam; 2008; 55(1):22-5. PubMed ID: 19024266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
    Kulp W; Greiner W; Graf von der Schulenburg JM
    Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.
    Brulhart L; Ciurea A; Finckh A; Notter A; Waldburger JM; Kyburz D; Gabay C
    Ann Rheum Dis; 2006 Sep; 65(9):1255-7. PubMed ID: 16540545
    [No Abstract]   [Full Text] [Related]  

  • 12. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.
    Naumann L; Huscher D; Detert J; Spengler M; Burmester GR; Buttgereit F
    Ann Rheum Dis; 2009 Dec; 68(12):1934-6. PubMed ID: 19910303
    [No Abstract]   [Full Text] [Related]  

  • 14. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 16. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor alpha agents.
    Martínez-Martínez MU; Cuevas-Orta E; Reyes-Vaca G; Baranda L; González-Amaro R; Abud-Mendoza C
    Ann Rheum Dis; 2007 Jan; 66(1):134-5. PubMed ID: 17178761
    [No Abstract]   [Full Text] [Related]  

  • 17. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
    Olofsson T; Englund M; Saxne T; Jöud A; Jacobsson LT; Geborek P; Allaire S; Petersson IF
    Ann Rheum Dis; 2010 Dec; 69(12):2131-6. PubMed ID: 20693274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
    Smolen JS; Weinblatt ME
    Ann Rheum Dis; 2008 Nov; 67(11):1497-8. PubMed ID: 18854512
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the 'VEDERA' trial.
    Shukla R; Emery P; Buch MH
    Rheumatology (Oxford); 2022 Feb; 61(2):868-869. PubMed ID: 34664622
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.
    Russell AS; Maksymowych WP; de Silva M
    Ann Rheum Dis; 2005 Dec; 64(12):1807. PubMed ID: 16284357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.